Diurnal Looking To Secure US Partner Soon For Alkindi
Hypogonadism Capsule Also Promising
With its adrenal insufficiency therapy Alkindi getting established in Europe, the UK biotech is in partnering discussions in the US where approval is expected before the end of the year.
You may also be interested in...
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
With the launch in Germany of Alkindi, Diurnal has kickstarted its plan of offering therapies that treat patients with cortisol deficiency diseases from birth right the way through to old age and the market is potentially a very lucrative one.
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.